Literature DB >> 31384186

Complications associated with the current sequential pharmacological management of early postnatal hypotension in extremely premature infants.

Rita P Verma1, Shaeequa Dasnadi2, Yuan Zhao3, Hegang H Chen4.   

Abstract

Early postnatal hypotension in premature infants is treated with escalating doses of vasopressor-inotropes (VI), followed by hydrocortisone if VI therapy fails. The adverse effects of this standard clinical practice have not been well reported. In a retrospective case-control study, we compared the complications associated with VI and hydrocortisone (HCVI) treatments in extremely low-birth-weight infants (≤1000 g) with contemporaneous normotensive medication-naïve controls via standard univariate and multivariate analyses. Birth weight, gestational age, and receipt of antenatal steroids did not differ between VI (n = 74) and control (n = 124) groups, while the occurrence of gestational diabetes mellitus and risks for patent ductus arteriosus, intraventricular-periventricular hemorrhage, spontaneous intestinal perforation, ventriculomegaly, and bronchopulmonary dsyplasia were higher in VI. Infants in the HCVI group (n = 69) had lower birth weight, gestational age, and receipt of antenatal steroids and higher risks for intraventricular-periventricular hemorrhage, bronchopulmonary dysplasia, air leaks, and patent ductus arteriosus than controls. Whereas the occurrences of spontaneous intestinal perforation, ventriculomegaly, and maternal diabetes mellitus did not differ, that of maternal hypertension trended to be lower in HCVI recipients (P = 0.06). In conclusion, hypotensive extremely low-birth-weight infants treated with VI or with HCVI are susceptible to intraventricular-periventricular hemorrhage, bronchopulmonary dysplasia, and patent ductus arteriosus. Furthermore, those who receive inotropes are at risk for spontaneous intestinal perforation and ventriculomegaly. Maternal diabetes mellitus increases the occurrence of hypotension, which responds to VI. Maternal hypertension does not contribute to VI responsive and tends to decrease the occurrence of VI-refractory hypotension.

Entities:  

Keywords:  Adverse effects; hydrocortisone; inotropes; neonatal hypotension

Year:  2019        PMID: 31384186      PMCID: PMC6650250          DOI: 10.1080/08998280.2019.1585732

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  2 in total

1.  Vasoactive medications in extremely low gestational age neonates during the first postnatal week.

Authors:  Laura E Miller; Matthew M Laughon; Reese H Clark; Kanecia O Zimmerman; Christoph P Hornik; Samia Aleem; P Brian Smith; Rachel G Greenberg
Journal:  J Perinatol       Date:  2021-03-23       Impact factor: 3.225

2.  Morbidity associated with patent ductus arteriosus in preterm newborns: a retrospective case-control study.

Authors:  Gianluca Terrin; Maria Di Chiara; Giovanni Boscarino; Valentina Metrangolo; Francesca Faccioli; Elisa Onestà; Antonella Giancotti; Violante Di Donato; Viviana Cardilli; Mario De Curtis
Journal:  Ital J Pediatr       Date:  2021-01-14       Impact factor: 2.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.